Prostate Cancer Clinical Consortium Clinical Research Site: Targeted Therapies
Abstract
The Prostate Cancer Research Program at Weill Cornell Medicine (WCM) and New York Presbyterian (NYP) is an internationally recognized prostate cancer (PC) clinical and translational research program. In 2017, we were awarded a Specialized Programs of Research Excellence (SPORE) grant in PC, highlighting the depth and breadth of our research. Since joining the Prostate Cancer Clinical Trials Consortium (PCCTC) as a Clinical Research Site in 2014, WCM has brought multiple high-impact and innovative therapeutic and biomarker studies to the PCCTC; enrolled more than 100 patients on clinical trials including 56 this past year; collected, processed, and analyzed over 500 tumor biopsy specimens, circulating tumor cells, and plasma and serum samples in a regulatory-compliant manner; complied with consortium developed quality assurance and quality control procedures; and led PC advocacy initiatives within the PCCTC. We are expanding our site to include NYP Brooklyn Methodist Hospital (NYPBMH) and Columbia University Medical Center (CUMC). The objective of this proposal is for WCM, together with NYPBMH and CUMC, to participate in the PCCTC as a multisite Clinical Research Site. Our overall aim is to translate our PC expertise in targeted therapies, PC imaging, immunotherapy, and correlative science into novel therapeutic approaches that can be tested in multi-institutional studies performed within the PCCTC. We intend to bring novel agents and new biomarker-driven trials directly to PC patients, including underrepresented minorities.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2023
- Accession Number
- AD1197734
Entities
People
- David Nanus
Organizations
- Cornell University